Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Matrixx Touts Survey Showing Pharmacists Support Zinc Remedies

This article was originally published in The Tan Sheet

Executive Summary

Matrixx Initiatives furthers its strategy to restore consumer trust in its troubled Zicam brand with a survey showing most pharmacists recommend zinc-based remedies for a cold.

You may also be interested in...



Matrixx settlement stumbles

A federal judge in Arizona objects to Matrixx Initiatives' proposed settlement of economic injury claims in 18 class-action filings. The Zicam maker said Sept. 3 it is working to resolve the procedural issues and still expects to finalize the settlement - totaling up to $35,000 (1"The Tan Sheet" Aug. 23, 2010). In an 2order filed Aug. 26, Judge Frederick Martone of the U.S. District Court for the District of Arizona rejects and denies the stipulation and joint request for dismissal without prejudice. Joining the economic injury claims with another case against Matrixx in a Chicago federal court would circumvent an earlier decision by a panel on multidistrict litigation, which rejected centralizing all actions in the Chicago court, Martone says. Scottsdale, Ariz.-based Matrixx faces hundreds of personal injury suits from consumers claiming they suffer anosmia from use of zinc-containing intranasal Zicam swab products

Odds Are Stacked Against Matrixx In Bid To Rescind Zicam Warning Letter

Matrixx Initiatives faces long odds against convincing FDA to withdraw a warning letter concerning the firm's Zicam intranasal products, food and drug lawyers say after the firm's request was rejected a second time

Zicam Case Shows FDA Takes Defining Adverse Events Seriously

Narrowly interpreting the definition of serious adverse events - compared to FDA's approach - is already costing Matrixx Initiatives at least $10 million dollars with the recall of its intranasal Zicam products

Related Content

Topics

UsernamePublicRestriction

Register

PS104644

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel